Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in Treatment Experienced Chinese Patients with pHLH
NCT05744063Phase 4Completed
- Sponsor
- Sobi
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emapalumab in primary hemophagocytic lymphohistiocytosis (HLH), sponsored by Sobi. Primary endpoint: Permanent Discontinuation of Study Drug Due to Emapalumab-related Adverse Event at 6 months. Started Feb 2023; status: completed.
02
Drugs
emapalumab
03
Conditions
primary hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05744063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744063.